Skip to Main content Skip to Navigation
Journal articles

Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice

Abstract : Hepatitis B virus (HBV) affects an estimated 250 million chronic carriers worldwide. Though several vaccines exist, they are ineffective for those already infected. HBV persists due to the formation of covalently closed circular DNA (cccDNA)-the viral minichromosome-in the nucleus of hepatocytes. Current nucleoside analogs and interferon therapies rarely clear cccDNA, requiring lifelong treatment. Our group identified GLP-26, a novel glyoxamide derivative that alters HBV nucleocapsid assembly and prevents viral DNA replication. GLP-26 exhibited single-digit nanomolar anti-HBV activity, inhibition of HBV e antigen (HBeAg) secretion, and reduced cccDNA amplification, in addition to showing a promising preclinical profile. Strikingly, long term combination treatment with entecavir in a humanized mouse model induced a decrease in viral loads and viral antigens that was sustained for up to 12 weeks after treatment cessation.
Complete list of metadatas

Cited literature [62 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-02875583
Contributor : Helene Strick-Marchand <>
Submitted on : Friday, June 19, 2020 - 6:16:22 PM
Last modification on : Wednesday, July 1, 2020 - 4:48:39 PM

Licence


Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

Identifiers

Collections

Citation

Franck Amblard, Sébastien Bouclé, Leda Bassit, Bryan Cox, Ozkan Sari, et al.. Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2020, 64 (2), ⟨10.1128/AAC.01701-19⟩. ⟨pasteur-02875583⟩

Share

Metrics

Record views

52

Files downloads

280